Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-02-20 Proxy Solicitation & In…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Ogłoszenie o NWZA w dniu 19.03.2026 r.
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice ('OGŁOSZENIE') for an Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie') of PolTREG S.A. It details the agenda, proposed changes to the company's statutes, and procedures for shareholder participation and proxy voting. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes, fitting the definition of a Proxy Solicitation & Information Statement.
2026-02-20 Polish
Zwołanie Nadzwyczajnego Walnego Zgromadzenia PolTREG S.A. na dzień 19 marca 2026 r. - Content (PL)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice convening an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) for PolTREG S.A. It cites specific articles of the Polish Commercial Companies Code and provides details on the meeting date, time, and location. It also mentions that the agenda and draft resolutions are attached. Since this is a solicitation/information document sent to shareholders regarding an upcoming meeting, it falls under Proxy Solicitation & Information Statement.
2026-02-20 Polish
Zamiar pozyskania finansowania i zainicjowanie procesu emisji akcji Spółki - Content (PL)
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from PolTREG S.A. regarding a planned capital increase through the issuance of new shares and the initiation of an accelerated book-building (ABB) process. It details the company's financing strategy, the intended use of proceeds for R&D projects, and the involvement of a major shareholder. As it describes a specific financing activity and capital structure change, it falls under the 'Capital/Financing Update' category.
2026-02-20 Polish
Pierwsza seria preparatu limfocytów modyfikowanych CAR-TREG do leczenia chorób neurozwyrodnieniowych (PTG-021) wytworzona w warunkach Dobrej Praktyki Produkcyjnej (GMP) - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from PolTREG S.A. regarding the successful manufacturing of a clinical trial product (PTG-021) under GMP conditions and the company's subsequent plans to apply for clinical trial authorization. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a general regulatory/corporate update regarding operational progress and clinical trial status, it falls under the RNS (Regulatory Filings) category.
2026-02-12 Polish
Potwierdzenie przez EMA kwalifikacji do złożenia wniosku o wydanie pozwolenia na dopuszczenie do obrotu w Unii Europejskiej preparatu komórek PolTREG-T1D - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from PolTREG S.A. regarding a significant regulatory milestone (eligibility letter from the EMA for a drug candidate). It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a specific corporate update regarding regulatory status and product development that does not fall into the other specialized categories, it is best classified as a general regulatory filing.
2026-02-10 Polish
Zmiana adresu strony internetowej PolTREG S.A. - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement from PolTREG S.A. informing shareholders about the launch of a new corporate website (poltreg.bio) and the transition from the old domain. It does not contain financial statements, audit results, or specific regulatory filings, but rather serves as a general corporate notification regarding communication channels. As it does not fit into specific categories like financial reports or M&A, it falls under the general regulatory announcement category.
2026-01-30 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.